FDA calendar · July 2016 · built from SEC filings

PDUFA dates July 2016: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in July 2016. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in July 2016

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

July 2016: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
July 11, 2016Xiidra (lifitegrast)BLCOFDA approval—ApprovedopenFDA Drugs@FDA
July 15, 2016Photrexa Viscous In Dextran 20% (riboflavin 5'-phosphate; riboflavin 5'-phosphate sodium)GKOSFDA approval—ApprovedopenFDA Drugs@FDA
July 21, 2016Dextenza (dexamethasone)OCULComplete Response Letter—CRL issuedFDA Complete Response Letters
July 22, 2016Viekira Xr (dasabuvir sodium; ombitasvir; paritaprevir; ritonavir)ABBVFDA approval—ApprovedopenFDA Drugs@FDA
July 27, 2016Adlyxin (lixisenatide)SNYFDA approval—ApprovedopenFDA Drugs@FDA

July 2016: dated readouts

No events in this view.

Questions

What PDUFA dates are in July 2016?

0 PDUFA dates fell in July 2016. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.